136 related articles for article (PubMed ID: 28338993)
41. Serenoa repens induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of STAT 3 signaling.
Che Y; Hou S; Kang Z; Lin Q
Oncol Rep; 2009 Aug; 22(2):377-83. PubMed ID: 19578780
[TBL] [Abstract][Full Text] [Related]
42. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways].
Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051
[No Abstract] [Full Text] [Related]
43. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor.
Muto A; Hori M; Sasaki Y; Saitoh A; Yasuda I; Maekawa T; Uchida T; Asakura K; Nakazato T; Kaneda T; Kizaki M; Ikeda Y; Yoshida T
Mol Cancer Ther; 2007 Mar; 6(3):987-94. PubMed ID: 17363492
[TBL] [Abstract][Full Text] [Related]
44. Isoliquiritigenin inhibits the growth of multiple myeloma via blocking IL-6 signaling.
Chen X; Wu Y; Jiang Y; Zhou Y; Wang Y; Yao Y; Yi C; Gou L; Yang J
J Mol Med (Berl); 2012 Nov; 90(11):1311-9. PubMed ID: 22648519
[TBL] [Abstract][Full Text] [Related]
45. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.
Pedranzini L; Dechow T; Berishaj M; Comenzo R; Zhou P; Azare J; Bornmann W; Bromberg J
Cancer Res; 2006 Oct; 66(19):9714-21. PubMed ID: 17018630
[TBL] [Abstract][Full Text] [Related]
46. Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling.
Heo SK; Noh EK; Seo HJ; Lee YJ; Koh S; Min YJ; Choi Y; Jo JC
PLoS One; 2022; 17(5):e0265958. PubMed ID: 35503759
[TBL] [Abstract][Full Text] [Related]
47. Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases.
Lee JH; Chiang SY; Nam D; Chung WS; Lee J; Na YS; Sethi G; Ahn KS
Cancer Lett; 2014 Apr; 345(1):140-8. PubMed ID: 24333736
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.
Ma J; Wang S; Zhao M; Deng XS; Lee CK; Yu XD; Liu B
BMC Cancer; 2011 Jun; 11():255. PubMed ID: 21679466
[TBL] [Abstract][Full Text] [Related]
49. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
Ma Y; Liu W; Zhang L; Jia G
Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
[TBL] [Abstract][Full Text] [Related]
50. DCZ0801, a novel compound, induces cell apoptosis and cell cycle arrest via MAPK pathway in multiple myeloma.
Zhang T; Li B; Feng Q; Xu Z; Huang C; Wu H; Chen Z; Hu L; Gao L; Liu P; Yang G; Zhang H; Lu K; Li T; Tao Y; Wu X; Shi J; Zhu W
Acta Biochim Biophys Sin (Shanghai); 2019 May; 51(5):517-523. PubMed ID: 30947332
[TBL] [Abstract][Full Text] [Related]
51. Arctiin is a pharmacological inhibitor of STAT3 phosphorylation at tyrosine 705 residue and potentiates bortezomib-induced apoptotic and anti-angiogenic effects in human multiple myeloma cells.
Lee JH; Kim C; Lee J; Um JY; Sethi G; Ahn KS
Phytomedicine; 2019 Mar; 55():282-292. PubMed ID: 30668440
[TBL] [Abstract][Full Text] [Related]
52. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells.
Wu W; Ma D; Wang P; Cao L; Lu T; Fang Q; Zhao J; Wang J
FEBS J; 2016 Mar; 283(5):834-49. PubMed ID: 26700310
[TBL] [Abstract][Full Text] [Related]
53. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
54. A Resveratrol Analogue Promotes ERKMAPK-Dependent Stat3 Serine and Tyrosine Phosphorylation Alterations and Antitumor Effects In Vitro against Human Tumor Cells.
Chelsky ZL; Yue P; Kondratyuk TP; Paladino D; Pezzuto JM; Cushman M; Turkson J
Mol Pharmacol; 2015 Sep; 88(3):524-33. PubMed ID: 26138072
[TBL] [Abstract][Full Text] [Related]
55. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
Khong T; Spencer A
Mol Cancer Ther; 2011 Oct; 10(10):1909-17. PubMed ID: 21859842
[TBL] [Abstract][Full Text] [Related]
56. Bavachin induces the apoptosis of multiple myeloma cell lines by inhibiting the activation of nuclear factor kappa B and signal transducer and activator of transcription 3.
Takeda T; Tsubaki M; Tomonari Y; Kawashima K; Itoh T; Imano M; Satou T; Nishida S
Biomed Pharmacother; 2018 Apr; 100():486-494. PubMed ID: 29477912
[TBL] [Abstract][Full Text] [Related]
57. [IL-6 Regulates the Chemosensitivity of Drug-Resistant Multiple Myeloma Cell Lines to Bortezomib through STAT3/Notch Signaling Pathway].
Liu Y; Sui JZ; Zhu LH; Dai Y; Dong HQ; Cheng P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1474-1481. PubMed ID: 36208252
[TBL] [Abstract][Full Text] [Related]
58. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
Tang S; Cheng B; Zhe N; Ma D; Xu J; Li X; Guo Y; Wu W; Wang J
Anticancer Drugs; 2018 Jan; 29(1):61-74. PubMed ID: 29049036
[TBL] [Abstract][Full Text] [Related]
59. Sprouty2 regulates proliferation and survival of multiple myeloma by inhibiting activation of the ERK1/2 pathway in vitro and in vivo.
Yao Y; Luo J; Bian Y; Sun Y; Shi M; Xia D; Niu M; Zhao K; Zeng L; Chen W; Li Z; Xu K
Exp Hematol; 2016 Jun; 44(6):474-482.e2. PubMed ID: 27016275
[TBL] [Abstract][Full Text] [Related]
60. Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells.
Hodge DR; Xiao W; Wang LH; Li D; Farrar WL
Cancer Biol Ther; 2004 Feb; 3(2):188-94. PubMed ID: 14726660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
